Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Croucher

Showing results (91-100 of 117) with videos related to

Pageof 12
Sort By:
Elife|June 10, 2020
Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinomaJordan F Hastings, Alvaro Gonzalez Rajal, Sharissa L Latham, et al.
Elife|May 13, 2021
A non-genetic, cell cycle-dependent mechanism of platinum resistance in lung adenocarcinomaAlvaro Gonzalez Rajal, Kamila A Marzec, Rachael A McCloy, et al.
Nature|July 13, 2013
Temporal regulation of EGF signalling networks by the scaffold protein Shc1Yong Zheng, Cunjie Zhang, David R Croucher, et al.
Cancer Research|September 24, 2010
Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cellsFalko Hochgräfe, Luxi Zhang, Sandra A O'Toole, et al.
Science Advances|November 28, 2025
Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastomaJeremy Z R Han, Monica Phimmachanh, Jordan F Hastings, et al.
Nature Communications|February 21, 2025
Activation of CAMK2 by pseudokinase PEAK1 represents a targetable pathway in triple negative breast cancerXue Yang, Xiuquan Ma, Tianyue Zhao, et al.
Biorxiv : the Preprint Server for Biology|February 26, 2024
Feed-forward stimulation of CAMK2 by the oncogenic pseudokinase PEAK1 generates a therapeutically "actionable" signalling axis in triple negative breast cancerXue Yang, Xiuquan Ma, Tianyue Zhao, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 18, 2025
JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancerSarah Alexandrou, Christine S Lee, Kristine J Fernandez, et al.
Breast Cancer Research : BCR|March 23, 2019
Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancerSean P Kennedy, Jeremy Z R Han, Neil Portman, et al.
Cancer & Metabolism|January 16, 2022
Prostate cancer cell proliferation is influenced by LDL-cholesterol availability and cholesteryl ester turnoverNikki L Raftopulos, Tinashe C Washaya, Andreas Niederprüm, et al.
Pageof 12

Showing results (91-100 of 117) with videos related to

Sort By:
Pageof 12
Elife|June 10, 2020
Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinomaJordan F Hastings, Alvaro Gonzalez Rajal, Sharissa L Latham, et al.
Elife|May 13, 2021
A non-genetic, cell cycle-dependent mechanism of platinum resistance in lung adenocarcinomaAlvaro Gonzalez Rajal, Kamila A Marzec, Rachael A McCloy, et al.
Nature|July 13, 2013
Temporal regulation of EGF signalling networks by the scaffold protein Shc1Yong Zheng, Cunjie Zhang, David R Croucher, et al.
Cancer Research|September 24, 2010
Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cellsFalko Hochgräfe, Luxi Zhang, Sandra A O'Toole, et al.
Science Advances|November 28, 2025
Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastomaJeremy Z R Han, Monica Phimmachanh, Jordan F Hastings, et al.
Nature Communications|February 21, 2025
Activation of CAMK2 by pseudokinase PEAK1 represents a targetable pathway in triple negative breast cancerXue Yang, Xiuquan Ma, Tianyue Zhao, et al.
Biorxiv : the Preprint Server for Biology|February 26, 2024
Feed-forward stimulation of CAMK2 by the oncogenic pseudokinase PEAK1 generates a therapeutically "actionable" signalling axis in triple negative breast cancerXue Yang, Xiuquan Ma, Tianyue Zhao, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 18, 2025
JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancerSarah Alexandrou, Christine S Lee, Kristine J Fernandez, et al.
Breast Cancer Research : BCR|March 23, 2019
Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancerSean P Kennedy, Jeremy Z R Han, Neil Portman, et al.
Cancer & Metabolism|January 16, 2022
Prostate cancer cell proliferation is influenced by LDL-cholesterol availability and cholesteryl ester turnoverNikki L Raftopulos, Tinashe C Washaya, Andreas Niederprüm, et al.
Pageof 12